Clinical Trials Browser

Phase 2 × Withdrawn × obinutuzumab × Clear all

NCT02371590 2018-02-23

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell